Test Price
2,800 AED✅ Home Collection Available
MYO15A Gene Deafness, Autosomal Recessive Type 3 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MYO15A للصمم الوراثي من النوع الثالث المتنحي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 and 9001:2015 Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counselor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We accept all major UAE medical insurers.
ضمان دقة بنسبة 99.9% عبر معالجة معتمدة وفق ISO 15189 وISO 9001:2015. خدمة سحب منزلي متميزة ونقل مبرد، واستشارة طبية بعد النتيجة، والتحقق من تغطية التأمين عبر الواتساب.
Comprehensive Overview
The MYO15A gene sequencing test detects pathogenic variants linked to autosomal recessive deafness type 3 (DFNB3), a congenital or prelingual severe-to-profound sensorineural hearing loss. This NGS-based analysis provides definitive molecular diagnosis, guides cochlear implantation candidacy, and supports familial recurrence risk assessment.
يكشف اختبار تتابع جين MYO15A عن الطفرات المسببة للصمم الوراثي المتنحي من النوع الثالث، ما يوفر تشخيصاً جزيئياً دقيقاً ويسهم في تخطيط التدخلات السمعية وتقدير الخطر الأسري.
| Feature | Our Test (MYO15A NGS) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision (Coverage) | >99% CDS coverage at 50× depth, specific to MYO15A | Variable; many genes sequenced but with lower target coverage |
| Methodology | Targeted NGS with Sanger confirmation of all variants | Whole Exome Sequencing (WES) plus Sanger validation |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
| Clinical Utility | Gold standard for DFNB3 confirmation and carrier testing | Broader search for unknown aetiologies; higher incidental findings rate |
Physician Insight & Safety Protocol
“A positive MYO15A result confirms hereditary deafness with implications for auditory habilitation and family planning. However, genetic data must be correlated with audiological phenotype and family history. A negative report does not exclude other genetic or environmental causes of hearing loss, and clinical follow-up remains essential.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠ Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. This genetic test is a diagnostic tool and does not directly determine drug regimens.
Safety Exclusion & Red Flags
- Not indicated for sudden sensorineural hearing loss (SSNHL) with acute onset; seek emergency ENT care.
- Unsuitable if patient lacks a clinical phenotype or family history consistent with DFNB3.
- Do not substitute for newborn hearing screening; it complements physiological tests.
- Red Flag Symptoms: Acute vertigo, unilateral tinnitus, otalgia, or facial nerve palsy require urgent otological evaluation, not elective genetic testing.
Patient FAQ & Clinical Guidance
Q1: What is the purpose of the MYO15A gene test?
This genetic test identifies mutations in the MYO15A gene responsible for autosomal recessive deafness type 3, enabling precise diagnosis, cochlear implant prognosis, and familial counseling. (يكشف هذا الاختبار عن الطفرات في جين MYO15A المسببة للصمم الوراثي المتنحي من النوع الثالث، ما يتيح تشخيصاً دقيقاً وتنبؤاً بالزرع القوقعي وإرشاداً أسرياً.)
Q2: How is the test performed and what is the sample requirement?
The requires a simple blood sample, extracted DNA, or a single drop of blood on an FTA card, all collected via our home service. (يُجرى الاختبار على عينة دم بسيطة أو حمض نووي مستخلص أو قطرة دم على بطاقة FTA، ويتم جمع العينة عبر خدمة السحب المنزلي.)
Q3: What is the turnaround time and how will I receive the results?
Results are delivered in 3–4 weeks via a secure, DHA-compliant electronic report with genetic counseling support included. (تصدر النتائج خلال 3–4 أسابيع عبر تقرير إلكتروني آمن متوافق مع هيئة الصحة بدبي، مع دعم استشارة وراثية.)
Compliant with Federal Decree-Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 (Consent for Minors), and UAE PDPL. Laboratory licensed by DHA/MOHAP (Facility License: 9834453). ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
For booking or insurance verification, contact WhatsApp: +971 54 548 8731. Home collection available daily from 8 AM to 11 PM.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians